Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · see citing works

Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163 · see citing works

The resurgence of platinum-based cancer chemotherapy

Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733 · see citing works

Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress

LeBel, C. P., Ischiropoulos, H., & Bondy, S. C. (1992) · Chemical Research in Toxicology · doi:10.1021/tx00026a012 · Cited by 2,694 · see citing works

ROS stress in cancer cells and therapeutic implications.

Pelicano, H., Carney, D., & Huang, P. (2004) · Drug resistance updates · doi:10.1016/j.drup.2004.01.004 · Cited by 1,992 · see citing works

Discovery of N -(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays

Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D. J., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,303 · see citing works

Angiostatin induces and sustains dormancy of human primary tumors in mice

O’Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,170 · see citing works

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

Godwin, A. K., Meister, A., O'Dwyer, P. J., Huang, C. S., Hamilton, T. C., & Anderson, M. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.3070 · Cited by 926 · see citing works

Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines

Yang, A. D., Fan, F., Camp, E. R., Buren, G. V., Liu, W., Somcio, R., Gray, M. J., Cheng, H. Y., Hoff, P. M., & Ellis, L. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0038 · Cited by 526 · see citing works

Controlling Tumor Growth by Modulating Endogenous Production of Reactive Oxygen Species

Laurent, A., Nicco, C., Chéreau, C., Goulvestre, C., Alexandre, J., Alvès, A., Lévy, E., Goldwasser, F., Panis, Y. H., Soubrane, O., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.948.65.3 · Cited by 506 · see citing works

Intracellular Reactive Oxygen Species Activate Src Tyrosine Kinase during Cell Adhesion and Anchorage-Dependent Cell Growth

Giannoni, E., Buricchi, F., Raugei, G., Ramponi, G., & Chiarugi, P. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.15.6391-6403.2005 · Cited by 455 · see citing works

Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer.

Talamonti, M. S., Roh, M. S., Curley, S. A., & Gallick, G. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116200 · Cited by 399 · see citing works

HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas

Gray, M. J., Zhang, J., Ellis, L. M., Semenza, G. L., Evans, D. B., Watowich, S. S., & Gallick, G. E. (2005) · Oncogene · doi:10.1038/sj.onc.1208513 · Cited by 372 · see citing works

Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: A p53-independent induction of p21WAF1/CIP1 via C/EBPβ

Chinery, R., Brockman, J. A., Peeler, M. O., Shyr, Y., Beauchamp, R. D., & Coffey, R. J. (1997) · Nature Medicine · doi:10.1038/nm1197-1233 · Cited by 334 · see citing works

Vessel Counts and Expression of Vascular Endothelial Growth Factor as Prognostic Factors in Node-Negative Colon Cancer

Takahashi, Y. (1997) · Archives of Surgery · doi:10.1001/archsurg.1997.01430290087018 · Cited by 329 · see citing works

Cisplatin-Induced Nephrotoxicity in Porcine Proximal Tubular Cells: Mitochondrial Dysfunction by Inhibition of Complexes I to IV of the Respiratory Chain

Kruidering, M., van de Water, B., de Heer, E., Mulder, G. J., & Nagelkerke, J. F. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36493-6 · Cited by 325 · see citing works

EphrinB Phosphorylation and Reverse Signaling

Palmer, A., Zimmer, M., Erdmann, K. S., Eulenburg, V., Porthin, A., Heumann, R., Deutsch, U., & Klein, R. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00488-4 · Cited by 305 · see citing works

New Roles for Src Kinases in Control of Cell Survival and Angiogenesis

Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)80664-9 · Cited by 302 · see citing works

Cisplatin Generates Superoxide Anion by Interaction with DNA in a Cell-Free System

Masuda, H., Tanaka, T., & Takahama, U. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2306 · Cited by 254 · see citing works

Activation of Src kinase in primary colorectal carcinoma: An indicator of poor clinical prognosis

Allgayer, H., Boyd, D. D., Heiss, M. M., Abdalla, E. K., Curley, S. A., & Gallick, G. E. (2002) · Cancer · doi:10.1002/cncr.10221 · Cited by 251 · see citing works

Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds

Witte, A.-B., Anestål, K., Jerremalm, E., Ehrsson, H., & Arnér, E. S. J. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.04.025 · Cited by 225 · see citing works

Treatment for Advanced Tumors: Src Reclaims Center Stage

Summy, J. M., & Gallick, G. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2692 · Cited by 224 · see citing works

Src activation regulates anoikis in human colon tumor cell lines

Windham, T. C., Parikh, N. U., Siwak, D. R., Summy, J. M., McConkey, D. J., Kraker, A. J., & Gallick, G. E. (2002) · Oncogene · doi:10.1038/sj.onc.1205989 · Cited by 216 · see citing works

Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity.

Sasada, T., Iwata, S., Sato, N., Kitaoka, Y., Hirota, K., Nakamura, K., Nishiyama, A., Taniguchi, Y., Takabayashi, A., & Yodoi, J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118668 · Cited by 201 · see citing works

Down-regulation of Vascular Endothelial Growth Factor in a Human Colon Carcinoma Cell Line Transfected with an Antisense Expression Vector Specific for c-src

Ellis, L. M., Staley, C. A., Liu, W., Fleming, R., Parikh, N. U., Bucana, C. D., & Gallick, G. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.2.1052 · Cited by 200 · see citing works

Improvement of the Therapeutic Index of Anticancer Drugs by the Superoxide Dismutase Mimic Mangafodipir

Alexandre, J., Nicco, C., Chéreau, C., Laurent, A., Weill, B. J., Goldwasser, F., & Batteux, F. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj049 · Cited by 200 · see citing works

Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells

Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1183-3 · Cited by 192 · see citing works

Impact of Insulin-Like Growth Factor Receptor-I Function on Angiogenesis, Growth, and Metastasis of Colon Cancer

Reinmuth, N., Fan, F., Liu, W., Parikh, A. A., Stoeltzing, O., Jung, Y. D., Bucana, C. D., Radinsky, R., Gallick, G. E., & Ellis, L. M. (2002) · Laboratory Investigation · doi:10.1097/01.lab.0000032411.41603.c2 · Cited by 174 · see citing works

Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells

Miyajima, A., Nakashima, J., Yoshioka, K., Tachibana, M., Tazaki, H., & Murai, M. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.363 · Cited by 170 · see citing works

Epidermal Growth Factor Receptor (EGFR) Ubiquitination as a Mechanism of Acquired Resistance Escaping Treatment by the Anti-EGFR Monoclonal Antibody Cetuximab

Lu, Y., Li, X., Liang, K., Luwor, R., Siddik, Z. H., Mills, G. B., Mendelsohn, J., & Fan, Z. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0589 · Cited by 170 · see citing works

Therapeutic Targeting of Neuropilin-2 on Colorectal Carcinoma Cells Implanted in the Murine Liver

Gray, M. J., Buren, G. V., Dallas, N. A., Xia, L., Wang, L., Yang, A. D., Somcio, R., Lin, Y. G., Lim, S. W., Fan, F., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm279 · Cited by 157 · see citing works

Cisplatin-induced activation of the EGF receptor

Benhar, M., Engelberg, D., & Levitzki, A. (2002) · Oncogene · doi:10.1038/sj.onc.1205980 · Cited by 146 · see citing works

Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases

Lesslie, D. P., Summy, J. M., Parikh, N. U., Fan, F., Trevino, J., Sawyer, T. K., Metcalf, C. A., Shakespeare, W. C., Hicklin, D. J., Ellis, L. M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603143 · Cited by 126 · see citing works

Src continues aging: current and future clinical directions

Kopetz, S., Shah, A. N., & Gallick, G. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1902 · Cited by 111 · see citing works

Site-Specific Differences in pp60c-src Activity in Human Colorectal Metastases

Termuhlen, P. M., Curley, S. A., Talamonti, M. S., Saboorian, M. H., & Gallick, G. E. (1993) · Journal of Surgical Research · doi:10.1006/jsre.1993.1046 · Cited by 108 · see citing works

Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line

Pengetnze, Y., Steed, M., Roby, K. F., Terranova, P. F., & Taylor, C. C. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.012 · Cited by 107 · see citing works

Expression and Activity of Src Regulate Interleukin-8 Expression in Pancreatic Adenocarcinoma Cells: Implications for Angiogenesis

Trevino, J. G., Summy, J. M., Gray, M. J., Nilsson, M. B., Lesslie, D. P., Baker, C. H., & Gallick, G. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3858 · Cited by 83 · see citing works

Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA

Gourdier, I., Crabbé, L., Andréau, K., Pau, B., & Kroemer, G. (2004) · Oncogene · doi:10.1038/sj.onc.1208047 · Cited by 79 · see citing works

SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells

George, J. A., Chen, T., & Taylor, C. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1822 · Cited by 78 · see citing works

Evidence of a novel redox-linked activation mechanism for the Src kinase which is independent of tyrosine 527-mediated regulation.

Pu, M., Akhand, A. A., Kato, M., Hamaguchi, M., Koike, T., Iwata, H., Sabe, H., Suzuki, H., & Nakashima, I. (1996) · PubMed · Cited by 66 · see citing works

Untitled work

(1996) · PubMed · Cited by 63 · see citing works

Protein cysteine sulfinic acid reductase (sulfiredoxin) as a regulator of cell proliferation and drug response

Lei, K., Townsend, D. M., & Tew, K. D. (2008) · Oncogene · doi:10.1038/onc.2008.132 · Cited by 61 · see citing works

Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis

Griffiths, G. J., Koh, M. Y., Brunton, V. G., Cawthorne, C., Reeves, N. A., Greaves, M., Tilby, M. J., Pearson, D. G., Ottley, C. J., Workman, P., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408550200 · Cited by 60 · see citing works

Rapid Determination of Glutathione Peroxidase and Thioredoxin Reductase Activities Using a 96-well Microplate Format: Comparison to Standard Cuvette-based Assays

Smith, A. D., Morris, V. C., & Levander, O. A. (2001) · International Journal for Vitamin and Nutrition Research · doi:10.1024/0300-9831.71.1.87 · Cited by 43 · see citing works

N-acetyl-l-cysteine fosters inactivation and transfer to endolysosomes of c-Src

Krasnowska, E. K., Pittaluga, E., Brunati, A. M., Brunelli, R., Costa, G., Spirito, M. D., Serafino, A., Ursini, F., & Parasassi, T. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.09.012 · Cited by 35 · see citing works

Expression and activation of lyn in macrophages treated in vitro with cisplatin: regulation by kinases, phosphatases and Ca2+/calmodulin

Singh, R. A. K., & Sodhi, A. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(98)00106-2 · Cited by 17 · see citing works

Upsides and Downsides of Reactive Oxygen Species for Cancer: The Roles of Reactive Oxygen Species in Tumorigenesis, Prevention, and Therapy

Gupta, S. C., Hevia, D., Patchva, S., Park, B., Koh, W., & Aggarwal, B. B. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4414 · Cited by 735 · see citing works

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

Frentzas, S., Simoneau, È., Bridgeman, V. L., Vermeulen, P., Foo, S., Kostaras, E., Nathan, M. R., Wotherspoon, A. C., Gao, Z., Shi, Y., et al. (2016) · Nature Medicine · doi:10.1038/nm.4197 · Cited by 456 · see citing works

Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation

Nassini, R., Gees, M., Harrison, S., Siena, G. D., Materazzi, S., Moretto, N., Failli, P., Preti, D., Marchetti, N., Cavazzini, A., et al. (2011) · Pain · doi:10.1016/j.pain.2011.02.051 · Cited by 326 · see citing works

Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

Mao, M., Tian, F., Mariadason, J. M., Tsao, C. C., Lemos, R., Dayyani, F., Gopal, Y. N. V., Jiang, Z.-Q., Wistuba, I. I., Tang, X. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1446 · Cited by 290 · see citing works

Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors

Araujo, J., & Logothetis, C. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.02.015 · Cited by 244 · see citing works

Regulation of Src Family Kinases in Human Cancers

Sen, B., & Johnson, F. M. (2011) · Journal of Signal Transduction · doi:10.1155/2011/865819 · Cited by 231 · see citing works

Targeted Delivery of Small Interfering RNA Using Reconstituted High-Density Lipoprotein Nanoparticles

Shahzad, M. M. K., Mangala, L. S., Han, H. D., Lü, C., Bottsford-Miller, J. N., Nishimura, M., Mora, E., Lee, J., Stone, R. L., Pecot, C. V., et al. (2011) · Neoplasia · doi:10.1593/neo.101372 · Cited by 220 · see citing works

SRC: A Century of Science Brought to the Clinic

Aleshin, A. A., & Finn, R. S. (2010) · Neoplasia · doi:10.1593/neo.10328 · Cited by 212 · see citing works

Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib

Broxterman, H. J., Gotink, K. J., & Verheul, H. M. W. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.07.001 · Cited by 206 · see citing works

The Role of Lysyl Oxidase in SRC-Dependent Proliferation and Metastasis of Colorectal Cancer

Baker, A., Cox, T. R., Bird, D., Lang, G., Murray, G. I., Sun, X., Southall, S. M., Wilson, J. R., & Erler, J. T. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq569 · Cited by 206 · see citing works

Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins

Minematsu, T., & Giacomini, K. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0731 · Cited by 196 · see citing works

Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer

Espey, M. G., Chen, P., Chalmers, B. P., Drisko, J., Sun, A. Y., Levine, M., & Chen, Q. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.03.007 · Cited by 190 · see citing works

Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation

Ding, Z., Hui, B., Shi, Y., Zhou, J., Peng, Y., Gu, C., Yang, H., Shi, G., Ke, A., Wang, X., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0816 · Cited by 178 · see citing works

Cancer drug resistance: redox resetting renders a way

Liu, Y., Li, Q., Zhou, L., Xie, N., Nice, E. C., Zhang, H., Huang, C., & Lei, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.8600 · Cited by 179 · see citing works

Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer

Johnson, F. M., Bekele, B. N., Feng, L., Wistuba, I. I., Tang, X., Tran, H. T., Erasmus, J. J., Hwang, L.-L., Takebe, N., Blumenschein, G. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5474 · Cited by 167 · see citing works

Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells

Nautiyal, J., Kanwar, S. S., Yu, Y., & Majumdar, A. P. N. (2011) · Journal of Molecular Signaling · doi:10.1186/1750-2187-6-7 · Cited by 149 · see citing works

Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells

Poh, A., O'Donoghue, R., & Ernst, M. (2015) · OncoTarget · doi:10.18632/oncotarget.4199 · Cited by 121 · see citing works

Src: a potential target for the treatment of triple-negative breast cancer

Tryfonopoulos, D. J., Walsh, S., Collins, D. M., Flanagan, L., Quinn, C., Corkery, B., McDermott, E. W. M., Evoy, D., Pierce, A., O’Donovan, N., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq757 · Cited by 138 · see citing works

The Role of Src in Colon Cancer and Its Therapeutic Implications

Chen, J., Elfiky, A. A., Han, M., Chen, C., & Saif, M. W. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.10.003 · Cited by 126 · see citing works

Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in human pancreatic cancer cells

Li, X., Zhu, F., Jiang, J., Sun, C., Wang, X., Shen, M., Tian, R., Shi, C., Xu, M., Peng, F., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.11.026 · Cited by 116 · see citing works

Oxaliplatin-induced oxidative stress in nervous system-derived cellular models: Could it correlate with in vivo neuropathy?

Mannelli, L. D. C., Zanardelli, M., Failli, P., & Ghelardini, C. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.019 · Cited by 106 · see citing works

Targeting DNA damage and repair: Embracing the pharmacological era for successful cancer therapy

Aziz, K., Nowsheen, S., Pantelias, G. E., Iliakis, G. E., Gorgoulis, V. G., & Georgakilas, A. G. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.010 · Cited by 104 · see citing works

Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth

Nagathihalli, N. S., Washington, M. K., & Merchant, N. B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1670 · Cited by 97 · see citing works

The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress

Chen, W., Lian, W., Yuan, Y., & Li, M. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1824-6 · Cited by 88 · see citing works

Regulation of Src Family Kinases during Colorectal Cancer Development and Its Clinical Implications

Jin, W. (2020) · Cancers · doi:10.3390/cancers12051339 · Cited by 86 · see citing works

Antioxidants decrease the apoptotic effect of 5-Fu in colon cancer by regulating Src-dependent caspase-7 phosphorylation

Fu, Y., Yang, G., Zhu, F., Peng, C., Li, W., Li, H., Kim, H.-G., Bode, A. M., Dong, Z., & Dong, Z. (2014) · Cell Death and Disease · doi:10.1038/cddis.2013.509 · Cited by 86 · see citing works

The Src Family of Protein Tyrosine Kinases: A New and Promising Target for Colorectal Cancer Therapy

Lieu, C. H., & Kopetz, S. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.012 · Cited by 86 · see citing works

Novel dual Src/Abl inhibitors for hematologic and solid malignancies

Schenone, S., Brullo, C., Musumeci, F., & Botta, M. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.499898 · Cited by 83 · see citing works

Plasticity of Cancer Cell Invasion—Mechanisms and Implications for Therapy

Boekhorst, V. T., & Friedl, P. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.07.005 · Cited by 86 · see citing works

Orally Administrated Hydrogel Harnessing Intratumoral Microbiome and Microbiota-Related Immune Responses for Potentiated Colorectal Cancer Treatment

Li, L., He, S., Liao, B., Wang, M., Lin, H., Hu, B., Lan, X., Shu, Z., Zhang, C., Yu, M., et al. (2024) · Research · doi:10.34133/research.0364 · Cited by 79 · see citing works

Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepatectomy for Metachronous Liver Metastases

Andreou, A., Kopetz, S., Maru, D. M., Chen, S. S., Zimmitti, G., Brouquet, A., Shindoh, J., Curley, S. A., Garrett, C. R., Overman, M. J., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31826b4dcc · Cited by 79 · see citing works

The multiple and enigmatic roles of guanylyl cyclase C in intestinal homeostasis

Arshad, N., & Visweswariah, S. S. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.07.028 · Cited by 76 · see citing works

Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells

Chang, A. Y., & Wang, M. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-267 · Cited by 73 · see citing works

Recent Insights into Mucinous Ovarian Carcinoma

Ricci, F., Affatato, R., Carrassa, L., & Damia, G. L. M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061569 · Cited by 71 · see citing works

Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer

Parseghian, C. M., Parikh, N. U., Wu, J. Y., Jiang, Z.-Q., Henderson, L., Tian, F., Pastor, B., Ychou, M., Raghav, K., Dasari, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3138 · Cited by 67 · see citing works

Role of c-Src in Carcinogenesis and Drug Resistance

Raji, L. M., Tetteh, A., & Amin, A. R. M. R. (2023) · Cancers · doi:10.3390/cancers16010032 · Cited by 67 · see citing works

Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Nam, H.-J., Im, S., Oh, D., Elvin, P., Kim, H., Yoon, Y., Min, A., Song, S., Han, S., Kim, T., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0109 · Cited by 65 · see citing works

Pharmacological Ascorbate Suppresses Growth of Gastric Cancer Cells with GLUT1 Overexpression and Enhances the Efficacy of Oxaliplatin Through Redox Modulation

Lu, Y., Wu, Q.-N., Chen, D.-L., Chen, L.-Z., Wang, Z., Ren, C., Mo, H., Ya, C., Sheng, H., Wang, Y.-N., et al. (2018) · Theranostics · doi:10.7150/thno.21745 · Cited by 65 · see citing works

Gene Array and Fluorescence <i>In situ</i> Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer

Arcaroli, J. J., Touban, B. M., Tan, A. C., Varella-Garcia, M., Powell, R. W., Eckhardt, S. G., Elvin, P., Gao, D., & Messersmith, W. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0066 · Cited by 64 · see citing works

Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer.

Sirvent, A., Bénistant, C., & Roche, S. (2012) · Europe PMC (PubMed Central) · Cited by 60 · see citing works

Src Inhibitors in Lung Cancer: Current Status and Future Directions

Rothschild, S. I., Gautschi, O. P., Haura, E. B., & Johnson, F. M. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.030 · Cited by 59 · see citing works

Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatin

Ceppi, P., Papotti, M. G., Monica, V., Iacono, M. L., Saviozzi, S., Pautasso, M., Novello, S., Mussino, S., Bracco, E., Volante, M., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0151 · Cited by 58 · see citing works

Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways

Raju, U., Riesterer, O., Wang, Z., Molkentine, D. P., Molkentine, J. M., Johnson, F. M., Glisson, B. S., Milas, L., & Ang, K. K. (2012) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2012.08.010 · Cited by 56 · see citing works

YES1: A Novel Therapeutic Target and Biomarker in Cancer

Garmendia, I., Redín, E., Montuenga, L. M., & Calvo, A. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0958 · Cited by 55 · see citing works

Mucinous ovarian cancer: A therapeutic review

Xu, W., Rush, J., Rickett, K., & Coward, J. I. G. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.015 · Cited by 54 · see citing works

Novel N-Substituted Amino Acid Hydrazone-Isatin Derivatives: Synthesis, Antioxidant Activity, and Anticancer Activity in 2D and 3D Models In Vitro

Tumosienė, I., Jonuškienė, I., Kantminienė, K., Mickevičius, V., & Petrikaitė, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157799 · Cited by 53 · see citing works

Src drives the Warburg effect and therapy resistance by inactivating pyruvate dehydrogenase through tyrosine-289 phosphorylation

Jin, Y., Cai, Q., Shenoy, A. K., Lim, S., Zhang, Y., Charles, S., Tarrash, M., Fu, X., Kamarajugadda, S., Trevino, J. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7159 · Cited by 53 · see citing works

Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29.

Chen, J., Huang, X., Qiao, L., & Katsifis, A. G. (2011) · PubMed Central · doi:10.3978/j.issn.2078-6891.2010.028 · Cited by 50 · see citing works

Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer

Reddy, S. M., Kopetz, S., Morris, J. S., Parikh, N. U., Qiao, W., Overman, M. J., Fogelman, D. R., Shureiqi, I., Jacob, C., Malik, Z., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0257-z · Cited by 55 · see citing works

Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium

Sharma, M. R., Wroblewski, K., Polite, B. N., Knost, J. A., Wallace, J. A., Modi, S., Sleckman, B. G., Taber, D., Vokes, E. E., Stadler, W. M., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9681-x · Cited by 49 · see citing works

The molecular rationale of Src inhibition in colorectal carcinomas

Gargalionis, A. N., Karamouzis, M. V., & Papavassiliou, A. G. (2014) · International Journal of Cancer · doi:10.1002/ijc.28299 · Cited by 47 · see citing works

Oxidative damage to guanine nucleosides following combination chemotherapy with 5-fluorouracil and oxaliplatin

Afzal, S., Jensen, S. A., Sørensen, J. B., Henriksen, T., Weimann, A., & Poulsen, H. E. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1700-2 · Cited by 47 · see citing works

Targeting Src in Mucinous Ovarian Carcinoma

Matsuo, K., Nishimura, M., Bottsford-Miller, J. N., Huang, J., Komurov, K., Armaiz-Peña, G. N., Shahzad, M. M. K., Stone, R. L., Roh, J., Sanguino, A. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3176 · Cited by 45 · see citing works

Long-Chain Fatty Acid Analogues Suppress Breast Tumorigenesis and Progression

Gluschnaider, U., Hertz, R., Ohayon, S., Smeir, E., Smets, M., Pikarsky, E., & Bar‐Tana, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0385 · Cited by 45 · see citing works

The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia

Overman, M. J., Ferrarotto, R., Raghav, K. P. S., George, B., Qiao, W., Machado, K. K., Saltz, L. B., Mazard, T., Vauthey, J., Hoff, P. M., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx288 · Cited by 43 · see citing works

The function of miR-200 family in oxidative stress response evoked in cancer chemotherapy and radiotherapy

Kozak, J., Jonak, K. E., & Maciejewski, R. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110037 · Cited by 42 · see citing works

Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells

Chen, B., Xu, X., Luo, J., Wang, H., & Zhou, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129663 · Cited by 42 · see citing works

Combined Inhibition of IGF-1R/IR and Src Family Kinases Enhances Antitumor Effects in Prostate Cancer by Decreasing Activated Survival Pathways

Dayyani, F., Parikh, N. U., Varkaris, A. S., Song, J. H., Moorthy, S., Chatterji, T., Maity, S. N., Wolfe, A. R., Carboni, J. M., Gottardis, M. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051189 · Cited by 40 · see citing works

Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

Liu, T., Hu, W., Dalton, H. J., Choi, H. J., Huang, J., Kang, Y., Pradeep, S., Miyake, T. M., Song, J. H., Wen, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1305 · Cited by 40 · see citing works

Cigarette smoke extract exposure induces EGFR-TKI resistance in EGFR-mutated NSCLC via mediating Src activation and EMT

Li, D., Zhang, L., Zhou, J., & Chen, H. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.12.007 · Cited by 39 · see citing works

Cancer therapy and cachexia

Thakir, T. M., Wang, A. R., Decker-Farrell, A. R., Ferrer, M., Guin, R. N., Kleeman, S. O., Levett, L. M., Zhao, X., & Janowitz, T. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191934 · Cited by 38 · see citing works

Multiplex Profiling of Biomarker and Drug Uptake in Single Cells Using Microfluidic Flow Cytometry and Mass Spectrometry

Zhang, X., Wei, X., Wu, C., Men, X., Wang, J., Bai, J., Sun, X., Wang, Y., Yang, T., Lim, C. T., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c12803 · Cited by 37 · see citing works

Dasatinib Is Preclinically Active against Src-Overexpressing Human Transitional Cell Carcinoma of the Urothelium with Activated Src Signaling

Levitt, J. M., Yamashita, H., Jian, W., Lerner, S. P., & Sonpavde, G. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0096 · Cited by 37 · see citing works

Sublethal concentrations of the platinum(II) complex [Pt(O,O′‐acac)(γ‐acac)(DMS)] alter the motility and induce anoikis in MCF‐7 cells

Muscella, A., Calabriso, N., Vetrugno, C., Urso, L., Fanizzi, F. P., Pascali, S. A. D., & Marsigliante, S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00782.x · Cited by 37 · see citing works

Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model

Scott, A. J., Song, E., Bagby, S. M., Purkey, A., McCarter, M. D., Gajdos, C., Quackenbush, K. S., Cross, B. R., Pitts, T. M., Tan, A. C., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187173 · Cited by 36 · see citing works

The long-term impact of oxaliplatin chemotherapy on rodent cognition and peripheral neuropathy

Fardell, J. E., Vardy, J. L., Monds, L. A., & Johnston, I. N. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.04.038 · Cited by 35 · see citing works

pH-responsive nanoprodrugs combining a Src inhibitor and chemotherapy to potentiate antitumor immunity via pyroptosis in head and neck cancer

Zhu, S., Ye, M., Ma, X., Wu, Z., Wan, S., Yang, S., Li, H., Xu, Z., & Sun, Z. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.10.051 · Cited by 35 · see citing works

Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src

Perez, M., Lucena-Cacace, A., Marín-Gómez, L. M., Padillo-Ruiz, J., Robles-Frias, M. J., Saez, C., Garcia-Carbonero, R., & Carnero, A. (2016) · Oncotarget · doi:10.18632/oncotarget.8880 · Cited by 34 · see citing works

Analysis of SRC Oncogenic Signaling in Colorectal Cancer by Stable Isotope Labeling with Heavy Amino Acids in Mouse Xenografts

Sirvent, A., Vigy, O., Orsetti, B., Urbach, S., & Roche, S. (2012) · Molecular &amp; Cellular Proteomics · doi:10.1074/mcp.m112.018168 · Cited by 33 · see citing works

SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer

Gururajan, M., Cavassani, K. A., Sievert, M. F., Duan, P., Lichterman, J. N., Huang, J.-M., Smith, B., You, S., Nandana, S., Chu, G. C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6398 · Cited by 33 · see citing works

Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling

Xiao, J., Xu, M., Hou, T., Huang, Y., Yang, C., & LI, J. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3784 · Cited by 35 · see citing works

Brain Metastases from Colorectal Cancer: Microenvironment and Molecular Mechanisms

Zang, Y.-W., Gu, X., Xiang, J., & Chen, Z. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131215784 · Cited by 33 · see citing works

Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer

Lee, M. S., & Kopetz, S. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.05.006 · Cited by 33 · see citing works

No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis

Zhou, S., Huang, Y., Wei, Y., Jiang, Z.-M., Zhang, Y.-D., Yang, Q., & Xie, D.-R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050925 · Cited by 31 · see citing works

The signalling axis mediating neuronal apoptosis in response to [Pt(O,O′-acac)(γ-acac)(DMS)]

Muscella, A., Calabriso, N., Vetrugno, C., Fanizzi, F. P., Pascali, S. A. D., & Marsigliante, S. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.03.007 · Cited by 31 · see citing works

Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival

Ptashkin, R. N., Pagan, C. A., Yaeger, R. D., Middha, S., Shia, J., O’Rourke, K. P., Berger, M. F., Wang, L., Cimera, R., Wang, J., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0352 · Cited by 31 · see citing works

Anti-proliferative potential of phytochemical fractions isolated from Simarouba glauca DC leaf

Jose, A., Kannan, E., & Madhunapantula, S. V. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03836 · Cited by 30 · see citing works

Src Family Tyrosine Kinases in Intestinal Homeostasis, Regeneration and Tumorigenesis

Sirvent, A., Mevizou, R., Naim, D., Lafitte, M., & Roche, S. (2020) · Cancers · doi:10.3390/cancers12082014 · Cited by 35 · see citing works

Anti-GPR56 monoclonal antibody potentiates GPR56-mediated Src-Fak signaling to modulate cell adhesion

Chatterjee, T., Zhang, S., Posey, T. A., Jacob, J., Wu, L., Yu, W., Francisco, L. E., Liu, Q. J., & Carmon, K. S. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100261 · Cited by 28 · see citing works

Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option

Willems, S. M., Schrage, Y. M., Bruijn, I. H. B., Szuhai, K., Hogendoorn, P. C. W., & Bovée, J. V. M. G. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-257 · Cited by 29 · see citing works

Src-family tyrosine kinases as therapeutic targets in advanced cancer

Gelman, I. H. (2011) · Frontiers in Bioscience · doi:10.2741/e287 · Cited by 28 · see citing works

Pathways of metastasis suppression in bladder cancer

Said, N. A., & Theodorescu, D. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9197-4 · Cited by 28 · see citing works

A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer

Heijink, D. M., Fehrmann, R. S. N., de Vries, E. G. E., Koornstra, J. J., Oosterhuis, D., van der Zee, A. G. J., KLEIBEUKER, J. H., & de Jong, S. (2011) · Oncogene · doi:10.1038/onc.2010.578 · Cited by 28 · see citing works

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer

Strickler, J. H., McCall, S. J., Nixon, A. B., Brady, J. C., Pang, H., Rushing, C. N., Cohn, A. L., Starodub, A., Arrowood, C., Haley, S. T., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-0042-9 · Cited by 27 · see citing works

Synergism from the combination of oxaliplatin with selected phytochemicals in human ovarian cancer cell lines.

Yunos, N. M., Beale, P. J., Yu, J. Q., & Huq, F. (2011) · PubMed · Cited by 26 · see citing works

The Src/PI3K/Akt signal pathway may play a key role in decreased drug efficacy in obesity‐associated cancer

Chen, J. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22572 · Cited by 26 · see citing works

Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells

Duong, H., Yi, Y. W., Kang, H. J., Bae, I., Jang, Y., Kwak, S., & Seong, Y. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2357 · Cited by 26 · see citing works

Upregulation of Tyrosine Kinase FYN in Human Thyroid Carcinoma: Role in Modulating Tumor Cell Proliferation, Invasion, and Migration

Zheng, J. J., Li, H., Xu, D., & Zhu, H. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2218 · Cited by 26 · see citing works

Src Family Kinase Inhibitor Saracatinib (AZD0530) Impairs Oxaliplatin Uptake in Colorectal Cancer Cells and Blocks Organic Cation Transporters

Morrow, C. J., Ghattas, M. A., Smith, C. G., Bönisch, H., Bryce, R. A., Hickinson, D. M., Green, T. P., & Dive, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0694 · Cited by 26 · see citing works

Phase I study of dasatinib (BMS‐354825) in Japanese patients with solid tumors

Takahashi, S., Miyazaki, M., Okamoto, I., Ito, Y., Ueda, K., Seriu, T., Nakagawa, K., & Hatake, K. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.02041.x · Cited by 24 · see citing works

The Tyrosine Kinase Inhibitor Dasatinib Induces a Marked Adipogenic Differentiation of Human Multipotent Mesenchymal Stromal Cells

Borriello, A., Caldarelli, I., Basile, M. A., Bencivenga, D., Tramontano, A., Perrotta, S., Ragione, F. D., & Oliva, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028555 · Cited by 24 · see citing works

Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells

Shi, M., Lou, B.-X., Ji, J., Shi, H., Zhou, C., Yu, Y., Liu, B., Zhu, Z., & Zhang, J. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2166-1 · Cited by 21 · see citing works

Prognostic relevance of Src activation in stage II-III colon cancer

Martínez-Pérez, J., Lopez-Calderero, I., Saez, C., Benavent, M., Limon, M. L., Gonzalez-Exposito, R., Soldevilla, B., Riesco-Martínez, M. C., Salamanca, J., Carnero, A., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.05.025 · Cited by 20 · see citing works

Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer

Iyer, K. K., van Erp, N. P., Tauriello, D. V. F., Verheul, H. M. W., & Poel, D. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102466 · Cited by 20 · see citing works

Src inhibitor dasatinib sensitized gastric cancer cells to cisplatin

Wang, H., Lu, Y., Wang, M., Shen, A., Wu, Y., Xu, X., & Li, Y. (2022) · Medical Oncology · doi:10.1007/s12032-022-01879-6 · Cited by 20 · see citing works

High hepatic expression of PDK4 improves survival upon multimodal treatment of colorectal liver metastases

Strowitzki, M. J., Radhakrishnan, P., Pavicevic, S., Scheer, J., Kimmer, G., Ritter, A. S., Tuffs, C., Volz, C., Vondran, F. W. R., Harnoss, J. M., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0406-9 · Cited by 20 · see citing works

BRAF V600E and SRC mutations as molecular markers for predicting prognosis and conversion surgery in Stage IV colorectal cancer

Shimada, Y., Muneoka, Y., Nagahashi, M., Ichikawa, H., Tajima, Y., Hirose, Y., Ando, T., Nakano, M., Sakata, J., Kameyama, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39328-6 · Cited by 19 · see citing works

Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines

Nannizzi, S., Veal, G. J., Giovannetti, E., Mey, V., Ricciardi, S., Ottley, C. J., Tacca, M. D., & Danesi, R. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1195-2 · Cited by 19 · see citing works

Dasatinib reduces 5-Fu-triggered apoptosis in colon carcinoma by directly modulating Src-dependent caspase-9 phosphorylation

Fu, Y., Yang, G., Xue, P., Guo, L., Yin, Y., Ye, Z., Peng, S., Qin, Y., Duan, Q., & Zhu, F. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0062-5 · Cited by 19 · see citing works

Changes in the levels of thioredoxin and indoleamine-2,3-dioxygenase activity in plasma of patients with colorectal cancer treated with chemotherapy

Cavia-Sáiz, M., Múñiz, P., Santiago, R. D., Herreros‐Villanueva, M., Girón, C. G., López, A. S., & Corral, M. J. C.-D. (2012) · Biochemistry and Cell Biology · doi:10.1139/o11-077 · Cited by 18 · see citing works

Role of activation of the protein tyrosine kinase, Src, in colorectal cancer chemoresistance

Kopetz, S. (2009) · Digital Commons-TMC (Texas Medical Center)

Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src

Perez, M., Lucena-Cacace, A., Marín-Gómez, L. M., Padillo-Ruiz, J., Robles-Frias, M. J., Saez, C., Garcia-Carbonero, R., & Carnero, A. (2016) · Oncotarget · doi:10.18632/oncotarget.8880 · Cited by 34 · see citing works

Combined activity of dasatinib (BMS-354825) and oxaliplatin in an orthotopic model of metastatic colorectal carcinoma

Lesslie, D. P., Parikh, N. U., Shah, A. N., Summy, J. M., Trevino, J. G., Hong, D. S., Donato, N. J., Lee, F. Y., & Gallick, G. E. (2006) · Cancer Research · Cited by 5 · see citing works

Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells

Shi, M., Lou, B.-X., Ji, J., Shi, H., Zhou, C., Yu, Y., Liu, B., Zhu, Z., & Zhang, J. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2166-1 · Cited by 21 · see citing works

Relationship of Src activity and prior oxaliplatin on outcomes after hepatectomy for metastatic colorectal cancer.

Morris, V. K., Parikh, N. U., Overman, M. J., Jiang, Z.-Q., Maru, D. M., Elvin, P., Kopetz, S., & Gallick, G. E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.3561